Skip to main content
SpringerLink
Log in

Ximelagatran, an Oral Direct Thrombin Inhibitor, Has a Low Potential for Cytochrome P450-Mediated Drug-Drug Interactions

  • Original Research Article
  • Published:
Clinical Pharmacokinetics Aims and scope Submit manuscript

Abstract

Background: Ximelagatran is an oral direct thrombin inhibitor currently in clinical development for the prevention and treatment of thromboembolic disorders. After oral administration, ximelagatran is rapidly absorbed and extensively bioconverted, via two intermediates (ethyl-melagatran and hydroxy-melagatran), to its active form, melagatran. In vitro studies have shown no evidence for involvement of cytochrome P450 (CYP) enzymes in either the bioactivation or the elimination of melagatran.

Objective: To investigate the potential of ximelagatran, the intermediates ethyl-melagatran and hydroxy-melagatran, and melagatran to inhibit the CYP system in vitro and in vivo, and the influence of three CYP substrates on the pharmacokinetics of melagatran in vivo.

Methods: The CYP inhibitory properties of ximelagatran, the intermediates and melagatran were tested in vitro by two different methods, using heterologously expressed enzymes or human liver microsomes. Diclofenac (CYP2C9), diazepam (CYP2C19) and nifedipine (CYP3A4) were chosen for coadministration with ximelagatran in healthy volunteers. Subjects received oral ximelagatran 24mg and/or diclofenac 50mg, a 10-minute intravenous infusion of diazepam 0.1 mg/kg, or nifedipine 60mg. The plasma pharmacokinetics of melagatran, diclofenac, diazepam, N-desmethyl-diazepam and nifedipine were determined when administered alone and in combination with ximelagatran.

Results: No inhibition, or only minor inhibition, of CYP enzymes by ximelagatran, the intermediates or melagatran was shown in the in vitro studies, suggesting that ximelagatran would not cause CYP-mediated drug-drug interactions in vivo. This result was confirmed in the clinical studies. There were no statistically significant differences in the pharmacokinetics of diclofenac, diazepam and nifedipine on coadministration with ximelagatran. Moreover, there were no statistically significant differences in the pharmacokinetics of melagatran when ximelagatran was administered alone or in combination with diclofenac, diazepam or nifedipine.

Conclusion: As ximelagatran did not exert a significant effect on the hepatic CYP isoenzymes responsible for the metabolism of diclofenac, diazepam and nifedipine, it is reasonable to expect that it would have no effect on the metabolism of other drugs metabolised by these isoenzymes. Furthermore, the pharmacokinetics of melagatran after oral administration of ximelagatran are not expected to be altered by inhibition or induction of CYP2C9, CYP2C19 or CYP3A4. Together, the in vitro and in vivo studies indicate that metabolic drug-drug interactions involving the major human CYP enzymes should not be expected with ximelagatran.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Table I
Table II
Table III
Table IV
Fig. 6

Similar content being viewed by others

Notes

  1. Use of tradenames is for product identification only and does not imply endorsement.

References

  1. Eriksson UG, Bredberg U, Hoffmann K-J, et al. Absorption, distribution, metabolism, and excretion of ximelagatran, an oral direct thrombin inhibitor, in rats, dogs, and humans. Drug Metab Dispos 2003; 31: 294–305

    Article  PubMed  CAS  Google Scholar 

  2. Eriksson UG, Bredburg U, Gislén K, et al. Pharmacokinetics and pharmacodynamics of ximelagatran, a novel oral direct thrombin inhibitor, in young, healthy male subjects. Eur J Clin Pharmacol 2003; 59:35–43

    PubMed  CAS  Google Scholar 

  3. Sarich TC, Eriksson UG, Mattsson C, et al. Inhibition of thrombin generation by the oral direct thrombin inhibitor ximelagatran in shed blood from healthy male subjects. Thromb Haemost 2002; 87: 300–5

    PubMed  CAS  Google Scholar 

  4. Gustafsson D, Antonsson T, Bylund R, et al. Effects of melagatran, a new low-molecular-weight thrombin inhibitor, on thrombin and fibrinolytic enzymes. Thromb Haemost 1998; 79: 110–8

    PubMed  CAS  Google Scholar 

  5. Gustafsson D, Nyström J, Carlsson S, et al. The direct thrombin inhibitor melagatran and its oral prodrug H 376/95: intestinal absorption properties, biochemical and pharmacodynamic effects. Thromb Res 2001; 101: 171–81

    Article  PubMed  CAS  Google Scholar 

  6. Elg M, Gustafsson D, Deinum J. The importance of enzyme inhibition kinetics for the effect of thrombin inhibitors in a rat model of arterial thrombosis. Thromb Haemost 1997; 78: 1286–92

    PubMed  CAS  Google Scholar 

  7. Elg M, Gustafsson D, Carlsson S. Antithrombotic effects and bleeding time of thrombin inhibitors and warfarin in the rat. Thromb Res 1999; 94: 187–97

    Article  PubMed  CAS  Google Scholar 

  8. Mehta JL, Chen L, Nichols WW, et al. Melagatran, an oral active-site inhibitor of thrombin, prevents or delays formation of electrically induced occlusive thrombus in the canine coronary artery. J Cardiovasc Pharmacol 1998; 31: 345–51

    Article  PubMed  CAS  Google Scholar 

  9. Eriksson BI, Carlsson S, Halvarsson M, et al. Antithrombotic effect of two low molecular weight thrombin inhibitors and a low-molecular weight heparin in a cavai vein thrombosis model in the rat. Thromb Haemost 1997; 78: 1404–7

    PubMed  CAS  Google Scholar 

  10. Mattsson C, Björkman J-A, Ulvinge J-C. Melagatran, hirudin and heparin as adjuncts to tissue-type plasminogen activator in a canine model of coronary artery thrombolysis. Fibrinolysis Proteolysis 1997; 11: 121–8

    Article  CAS  Google Scholar 

  11. Eriksson BI, Arfwidsson A-C, Frison L, et al. A dose-ranging study of the oral direct thrombin inhibitor, ximelagatran, and its subcutaneous form, melagatran, compared with dalteparin in the prophylaxis of thromboembolism after hip or knee replacement: METHRO I. MElagatran for THRombin inhibition in Orthopaedic surgery. Thromb Haemost 2002; 87: 231–7

    PubMed  CAS  Google Scholar 

  12. Eriksson BI, Bergqvist D, Kälebo P, et al. Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial. Lancet 2002; 360: 1441–7

    Article  PubMed  CAS  Google Scholar 

  13. Francis CW, Davidson BL, Berkowitz SD, et al. Ximelagatran versus warfarin for the prevention of venous thromboembolism after total knee arthroplasty: a randomized, double-blind trial. Ann Intern Med 2002; 137: 648–55

    PubMed  CAS  Google Scholar 

  14. Eriksson BI, Agnelli G, Cohen AT, et al. Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement: The METHRO III study. Thromb Haemost 2003; 89: 288–96

    PubMed  CAS  Google Scholar 

  15. Heit JA, Colwell CW, Francis CW, et al. Comparison of the oral direct thrombin inhibitor ximelagatran with enoxaparin as prophylaxis against venous thromboembolism after total knee replacement: a phase 2 dose-finding study. Arch Intern Med 2001; 161: 2215–21

    Article  PubMed  CAS  Google Scholar 

  16. Francis CW, Berkowitz SD, Comp PC, et al. Randomized, double-blind, comparison of ximelagatran, an oral direct thrombin inhibitor, and warfarin to prevent venous thromboembolism (VTE) after total knee replacement (TKR) [abstract]. Blood 2002; 100(11): 82a

    Google Scholar 

  17. Eriksson H, Wåhlander K, Gustafsson D, et al. A randomized, controlled, dose-guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I. J Thromb Haemost 2003; 1: 41–7

    Article  PubMed  CAS  Google Scholar 

  18. Petersen P, Grind M, Adler J, SPORTIF II Investigators. Ximelagatran versus warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: SPORTIF II. a dose-guiding, tolerability and safety study. J Am Coll Cardiol 2003; 42: 1445–51

    Article  Google Scholar 

  19. Formation of melagatran from H 415/04 in human intestine, kidney and lung microsomes. Mölndal: DMPK and Bioanalytical Chemistry, AstraZeneca, 2000. (Data on file)

  20. Andersson TB. Activation of ximelagatran, melagatran’s prodrug [abstract]. Drug Metab Rev 2001; 33 Suppl. 1: 8

    Google Scholar 

  21. Bapiro TE, Egnell AC, Hasler JA, et al. Application of higher throughput screening (HTS) inhibition assays to evaluate the interaction of antiparasitic drugs with cytochrome P450s. Drug Metab Dispos 2001; 29: 30–5

    PubMed  CAS  Google Scholar 

  22. Masimirembwa CM, Otter C, Berg M, et al. Heterologous expression and kinetic characterization of human cytochrome P-450: validation of a pharmaceutical tool for drug metabolism research. Drug Metab Dispos 1999; 27: 1117–21

    PubMed  CAS  Google Scholar 

  23. Larsson M, Lögren U, Ahnoff M, et al. Determination of melagatran, a novel, direct thrombin inhibitor, in human plasma and urine by liquid chromatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2002; 766: 47–55

    Article  PubMed  CAS  Google Scholar 

  24. Guengerich FP. Role of cytochrome P450 enzymes in drug-drug interactions. Adv Pharmacol 1997; 43: 7–35

    Article  PubMed  CAS  Google Scholar 

  25. The effect of oral H 376/95 on the pharmacokinetics of diclofenac in healthy male volunteers. Mölndal: Experimental Medicine, AstraZeneca, 2002. (Data on file)

  26. Morin S, Loriot MA, Poirier JM, et al. Is diclofenac a valuable CYP2C9 probe in humans? Eur J Clin Pharmacol 2001; 56: 793–7

    Article  PubMed  CAS  Google Scholar 

  27. Andersson T, Miners JO, Veronese ME, et al. Diazepam metabolism by human liver microsomes is mediated by both Smephenytoin hydroxylase and CYP3A isoforms. Br J Clin Pharmacol 1994; 38: 131–7

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

The authors acknowledge the valuable contribution of Dr Thierry Duvauchelle and colleagues at Aster, Paris, France, in the planning and conducting of the clinical studies. The authors thank Dr Cyriaue J. Sagan and colleagues at Cephac, Saint-Benoît, France, for performing the bioanalysis for the clinical studies. We also wish to thank Annika Janefelt and Marie Ahlström at AstraZeneca for performing the in vitro assays. The study was sponsored by AstraZeneca.

Author information

Authors and Affiliations

  1. Experimental Medicine, AstraZeneca R&D Mölndal, S-431 83, Mölndal, Sweden

    Eva Bredberg, Tommy B. Andersson, Lars Frison, Annelie Thuresson, Susanne Johansson, Maria Eriksson-Lepkowska, Marita Larsson & Ulf G. Eriksson

Authors
  1. Eva Bredberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tommy B. Andersson
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lars Frison
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Annelie Thuresson
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Susanne Johansson
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Maria Eriksson-Lepkowska
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Marita Larsson
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Ulf G. Eriksson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Eva Bredberg.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bredberg, E., Andersson, T.B., Frison, L. et al. Ximelagatran, an Oral Direct Thrombin Inhibitor, Has a Low Potential for Cytochrome P450-Mediated Drug-Drug Interactions. Clin Pharmacokinet 42, 765–777 (2003). https://doi.org/10.2165/00003088-200342080-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003088-200342080-00005

Keywords

Search

Navigation